EGFR and non-small cell lung carcinoma: A small study in China with an interesting design enrolled 24 patients with stage IIIA-N2 NSCLC to receive pre-operatively either erlotinib or gemcitabine/carboplatin (GC) based on genomic testing results (EGFR mutant + versus EGFR wild type, respectively) [64].